Last data update: Nov 04, 2024. (Total: 48056 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Boer KR[original query] |
---|
Operating characteristics of a tuberculosis screening tool for people living with HIV in out-patient HIV care and treatment services, Rwanda
Turinawe K , Vandebriel G , Lowrance DW , Uwinkindi F , Mutwa P , Boer KR , Mutembayire G , Tugizimana D , Nsanzimana S , Pevzner E , Howard AA , Gasana M . PLoS One 2016 11 (9) e0163462 BACKGROUND: The World Health Organization (WHO) 2010 guidelines for intensified tuberculosis (TB) case finding (ICF) among people living with HIV (PLHIV) includes a recommendation that PLHIV receive routine TB screening. Since 2005, the Rwandan Ministry of Health has been using a five-question screening tool. Our study objective was to assess the operating characteristics of the tool designed to identify PLHIV with presumptive TB as measured against a composite reference standard, including bacteriologically confirmed TB. METHODS: In a cross-sectional study, the TB screening tool was routinely administered at enrolment in outpatient HIV care and treatment services at seven public health facilities. From March to September 2011, study enrollees were examined for TB disease irrespective of TB screening outcome. The examination consisted of a chest radiograph (CXR), three sputum smears (SS), sputum culture (SC) and polymerase chain reaction line-probe assay (Hain test). PLHIV were classified as having "laboratory-confirmed TB" with positive results on SS for acid-fast bacilli, SC on Lowenstein-Jensen medium, or a Hain test. RESULTS: Overall, 1,767 patients were enrolled and screened of which; 1,017 (57.6%) were female, median age was 33 (IQR, 27-41), and median CD4+ cell count was 385 (IQR, 229-563) cells/mm3. Of the patients screened, 138 (7.8%) were diagnosed with TB of which; 125 (90.5%) were laboratory-confirmed pulmonary TB. Of 404 (22.9%) patients who screened positive and 1,363 (77.1%) who screened negative, 79 (19.5%) and 59 (4.3%), respectively, were diagnosed with TB. For laboratory-confirmed TB, the tool had a sensitivity of 54.4% (95% CI 45.3-63.3), specificity of 79.5% (95% CI 77.5-81.5), PPV of 16.8% and NPV of 95.8%. CONCLUSION: TB prevalence among PLHIV newly enrolling into HIV care and treatment was 65 times greater than the overall population prevalence. However, the performance of the tool was poorer than the predicted performance of the WHO recommended TB screening questions. |
HIV surveillance in Rwanda: Readiness assessment to transition from antenatal care-based to prevention of mother to child transmission program-based HIV surveillance
Balisanga H , Mutagoma M , Remera E , Kayitesi C , Kayirangwa E , Dee J , Malamba S , Boer KR , Hedt-Gauthier B , Umugwaneza P , Nsanzimana S . Int J Infect Dis 2016 52 62-67 BACKGROUND: For efficiency and ethical considerations, in 2013 the World Health Organization (WHO) recommended to investigate transitioning from antenatal clinic-based surveillance to the prevention of mother to child transmission- (PMTCT-) based routine data. An assessment on the readiness for this transition was carried out in Rwanda in 2011 and 2013. METHODS: This assessment applied the WHO recommended methods which compares individual HIV rapid testing at site and antenatal surveillance results in all existing 30 sites involving 13,292 women. In addition, PMTCT HIV-testing quality assurance and PMTCT routine data quality were assessed in 27 out of 30 sites. RESULTS: All sentinel sites provided PMTCT services and had a high uptake of HIV testing (more than 90%). In all sites, PMTCT data were recorded in longitudinal and standardized ANC registers. Twenty six out of 27 sites had HIV result completeness above 90%. Positive percent agreement (97.5%) and negative percent agreement (99.9%) were observed between routine PMTCT and sero-surveillance HIV test results. Of 27 sites, 25 scored more than 80% in all phases of HIV testing quality assurance. CONCLUSIONS: According to WHO standards, Rwanda antenatal clinic HIV sero-surveillance is ready to transition to PMTCT-based sero-surveillance. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Nov 04, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure